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Abstract
We consider modeling jointly microarray RNA expression and DNA copy number data. We propose Bayesian mixture models
that define latent Gaussian probit scores for the DNA and RNA, and integrate between the two platforms via a regression of
the RNA probit scores on the DNA probit scores. Such a regression conveniently allows us to include additional sample
specific covariates such as biological conditions and clinical outcomes. The two developed methods are aimed respectively
to make inference on differential behaviour of genes in patients showing different subtypes of breast cancer and to predict
the pathological complete response (pCR) of patients borrowing strength across the genomic platforms. Posterior inference
is carried out via MCMC simulations. We demonstrate the proposed methodology using a published data set consisting of
121 breast cancer patients.
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Copy number and arrayCGH. Human beings have two
copies of each gene, defined as a segment of DNA. The normal
copy number of a gene is therefore two. Copy number aberration
(CNA) refers to cytogenetic events in which the DNA replication
process is disrupted such that the gene either is replicated multiple
times (copy number gains) or loses one or both copies (copy
number loss) in newly generated cells. Comparative Genomic
Hybridization (CGH) has emerged as a dominant technique for
detecting CNA [1], especially when combined with microarrays.
The resulting arrayCGH techniques [2], [3], [4] and [5] measure
thousands or millions of genomic targets or ‘‘probes’’ that are
spotted or printed on a glass surface. These probes usually span the
whole genome with a resolution of the order ranging from 1 MB
(one million base pairs) for BAC (bacterial artificial chromosome),
to 50–100 kb (kilo base pairs) for more recent microarrays. In an
arrayCGH experiment, a DNA test sample of interest is labeled
with a dye (say Cy3) and then mixed with a diploid reference sample
labeled with a different dye (say Cy5). The combined sample is
then hybridized to the microarrays and intensities of both colors
are measured through an imaging process. The quantity of interest
is the log2 ratio of the two intensities for each color. The
collection of the intensity ratios then provide useful information
about genome-wide changes in copy numbers between the two
samples. Since the reference sample is presumed to be diploid, the
intensity ratio is determined by the copy number of the DNA in
the test sample. If the copy number of the test sample is also two,
then the theoretical log2 intensity ratio equals zero. If there is a
single copy loss in the test sample, the theoretical ratio is
log2 1=2~{1 assuming all the cells in the test sample lost one
copy of the DNA fragment. If there is a single copy gain, the
theoretical ratio is log2 3=2~0:58: Multiple copy gains are called
amplifications, and the corresponding theoretical intensity ratios are
log2 4=2 , log2 5=2 , etc. When both copies are lost, the
theoretical ratio is {? and a large negative value is usually
observed in experiments.
Integration of DNA copy number and RNA
expression. Expression microarrays measure RNA expression
which, by the central dogma of molecular biology, are resulted
from the transcription of DNAs. Microarray technology for
measuring RNA gene expression has been well known to the
statistical community, and its review is omitted here. Naturally, we
are prone to think that CNAs impact the intensities of the relative
RNA expressions in that more copies of DNA should lead to
higher levels of RNA expression. It is therefore of great interest to
study the intensity of such interaction, if there is any, between
aCGH and RNA expression measurements on different genes.
Gene expression and copy number variation data have been
broadly studied, to assess differential expression of genes [6] and to
find segments along the DNA that show CNAs [7], [8]. Statistical
and computational models for integrating different types of data
are becoming a popular topic in the recent literature, even though
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only few considered full model-based approaches. [9] was among
the earliest to investigate the direct association between the two
types of data in breast cancer cell lines and tissue samples, and
their approach was based mainly on descriptive statistics. Van
Wieringen and Van de Wiel [10], attempting to mitigate the high
noise in the raw expression measurements of the DNA and RNAs,
proposed a sampling model for RNA expression incorporating
estimated probabilities of corresponding CNAs. They subsequent-
ly developed nonparametric adaptive tests to study whether the
estimated copy number variations in the DNA level would induce
differential gene expression at the RNA level. More recently [11]
presented a double-layered mixture model (DLLM ) that directly
modeled segmental patterns in the copy number data to produce
CNA profiles, and simultaneously scored the association between
copy number and gene expression data. The DLMM assigned
high scores to elevated or reduced expression measurement only if
the expression changes are observed consistently across samples
with copy number aberration.
An important biological premise to the description of the model
is that by integrating DNA copy number and RNA expression
data, we will gain more knowledge about the underlying biological
process. For example, a high or low correlation between a copy
number aberration (CNA) for a gene marker and its abnormal
RNA expression would indicate different carcinogenic mechanism
and therefore different treatment selections [12] [13].
We describe a Bayesian Mixture Model that converts the noisy
raw intensity measurement of the DNA and RNAs into probability
of expression, which are subsequently modeled as latent param-
eters. Thus the integration of the two platforms is realized by joint
modeling the probabilities of expression through a probit
regression. Our aim, however, is not only to evaluate the relative
contribution of large genetic variants such as CNAs, to gene
expression but also make inference using both differential
expression of the genes and differential copy number variations
of the same set of genes. Moreover our full model-based approach
allows us, after new information on the patients in the study are
acquired, to exploit the latent integrated structure of our model
and achieve better predictive performances for the clinical
outcome of new patients coming into the study.
In the next paragraph we present a motivating example with
matched arrayCGH and microarray samples from breast cancer
patients. In the materials and methods section we introduce
probability models with a particular focus on the probit regression
that allows for integration of both platforms, along with some
simulation studies. Thus, in the result section, the focus is on
posterior inference of the interaction between the two platforms,
differential behaviour, which takes into account both differential gene
expression and differential CNA, and prediction of the pCR of
patients after treatment. A final remark is provided in the
discussion section.
Motivating Example
We consider data in breast cancer consisting of 121 patients
from three disease subgroups, ER+, HER2+, and triple negative
(TN). ER+ patients have present estrogen receptors – a protein
related to hormone and regulation of gene expression – in their
cancer cells. HER2+ patients are instead those whose tumor cells
test positive for a protein called human epidermal growth factor
receptor 2. Finally TN patients lack three ‘‘receptors’’ in their
cancer cells: ER, HER2, and progesterone receptors. ER+ and
HER2+ patients were therefore collapsed in the same group, in
order to compare TN patients versus others.
On a slightly reduced set of 116 patients we have a measure,
formalized as a dichotomous variable, on their positive or negative
pCR to treatment. Numerosities are specified in the table 1.
The mRNA expression data was obtained with Affymetrix
U133A gene chips. The data was normalized with MAS5
algorithm, scaled to target intensity of 600 and log2 transformed.
The expression profiles of the cancers are available at GEO
accession number GSE22093 [14]. The DNA copy number data
was generated with Agilent 4x44K CGH arrays, processed as log2
ratios of the intensities of the two colors, and is available at
ArrayExpress accession number E-TABM-584.
ArrayCGH and microarray RNA experiments have been
performed using the 121 breast samples to obtain the copy
number data on 22,944 probes and RNA expression data for
11,306 genes. We then mapped 22,944 probes to the 11,306
genes, which gave us a matching between the probe ids on the
aCGH and the gene ids on the microarrays.
Materials and Methods
Ethics Statement
All the research used public data, published in 2009 in the
following paper: ‘‘Molecular characterization of breast cancer with
high-resolution oligonucleotide comparative genomic hybridiza-
tion array’’ written by Andre F. et al. and published in Clinical
Cancer Research [14].
Sampling model for w and y
On arrayCGH, the experimental unit is probe b belonging to
gene g. On RNA microarray, the experimental unit is gene g.
Denote wbt the log2 intensity ratio for probe b at sample t, and
ygt the RNA expression level for gene g at sample t, b~1,:::B
g~1,:::,G, and t~1,:::T : Denoting fb [ gg the set of
arrayCGH probes corresponding to gene g, the matched copy
number and RNA expression data for sample t is then
f(wbt)b[g, ygtg:
We propose mixture models for w and y and introduce latent
variables representing the differential expression status of the DNA
and RNA, respectively. We then integrate the two models by
constructing a prior probit regression linking the latent variables
from both platforms.
We use a mixture model [15] to introduce trinary latent
indicator variables for the CNA state for each probe and the
differential expression (DE) state for each gene. Specifically, let ewbt
take values in the set f{1,0:1g , respectively corresponding to the
copy-loss (v2 copy number), copy-neutral (~2 copy number),
and copy-gain (w2 copy number) states and e
y
gt take values in the
Table 1. Contingency table to classify patients with respect




HER2 or both TOT
Positive pCR 20 11 31
No pCR 33 52 85
Missing 3 2 5
TOT 56 65 121
doi:10.1371/journal.pone.0068071.t001
Bayesian Models and Integration Genomic Platforms
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e68071
set f{1,0:1g , respectively corresponding to the under-, normal-,
and over-expression states. Conditional on ewbt and e
y
gt , the
sampling models for copy number log2 ratios wbt and for gene
expression ygt are given by
fw(wbtDewbt)~d



























In (2), the mixture model for gene expression data ygt includes a
gene effect mg and a sample effect at . This is not the case in the
mixture model for aCGH data wbt . The main reason is because
wbt is already a log ratio between the cancer sample copy number
and the reference sample copy number and therefore the
Figure 1. Graphical representation of the model for assessment of gene differential behaviour (A) and the prediction model (B).
Boxes refer to variables in the model, where latent variables are represented by dotted line boxes. Circles refere to parameters, where the red ones
are the indicators used for posterior inference.
doi:10.1371/journal.pone.0068071.g001
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corresponding effects should have canceled out by taking the ratio.
The sampling model is indexed by n2b and s
2
g representing normal





g define the tail overdispersion
with respect to normality, associated with copy losses or gains for
aCGH and under- or over-expression for microarrays.
Latent probit scores and probit regression
Anticipating the integration of both platforms using a regression
model, we further introduce latent Gaussian variables zwbt and z
y
gt

























Before we introduce the probit regression for integration, we
present a prior for zwbt that allows for inference of different CNAs
across different conditions, in our case of breast cancer data,
different subtypes of breast cancer. Let xt is a clinical categorical









where fxt~jg,j~1,0 respectively if the patient belongs to TN
subgroup or not, zwb , a probe-specific mean, describes a baseline
CNA status (e.g., a reference subtype) and dwg a trinary indicator
accounting for differential CNA in the two subtypes, following a
prior distribution given by
dwg ~
{1 with prob: 0:2
0 with prob: 0:6
1 with prob: 0:2
8>><
>>:
The integration of the two platforms is easily done using the
latent probit scores and a linear model. First, we introduce a gene-






Keeping in mind that there is a natural biological causal
relationship between DNA copy number change and altered gene








where xt is the clinical binary covariate mentioned above, while
dyg and d
yw
g trinary indicators accounting respectively for
differential gene expression in TN subgroup and interaction
between the two measurement for gene g , following similar prior
to the one mentioned above for dwg .
Markov dependence across probes. A Markov depen-
dence is assumed across the probes and it is defined in the
following conditional prior on the probe specific effect. Define
zw~(zw1 ,:::,z
w
B): Assuming that the index b is ordered according to
Figure 2. Posterior probabilities of positive interaction between the two platforms (A), differential CNA (B) and differential joint
behaviour (C) after simulation 2. The red dots highlight posterior probabilities of genes which are claimed by the model to show respectively
positive interaction between the two platforms, differential CNA and differential joint behaviour.
doi:10.1371/journal.pone.0068071.g002
(3)
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Figure 3. Posterior probabilities of differential CNA (on the x-axis) and differential expression (y-axis) obtained respectively
through the marginal models on CNA data and gene expression data (A). Black dots highlight posterior probabilities of genes which are
claimed by the model to show joint differential behaviour (A). Comparison between differences in means of the gene expression data and posterior
Bayesian Models and Integration Genomic Platforms
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locus proximity on the chromosome, the dependence across






for b [ f2,:::,Bg: In this formulation the parameters
b~(b1,:::,bb{1) can be directly interpreted as partial correlation
coefficients, defining the strength of dependence between log2
ratios associated with probes that are adjacent on the chromo-
some.
Priors. The last step is the specification of the priors for the
set of parameters that index the sampling model. We assume
conditionally conjugate priors. Denoting G(a,b) a gamma





































for b [ f1,2,:::,B{1g , with t2v1 so that the marginal variance
of zb ’s is bounded above. Note that this model assumes that
adjacent probes are equally correlated, characterized by b ’s and
t2. Alternatively, one could model the correlation between probes
as a function of their genomics distances, and this can be easily
achieved by modeling bb{1 as a distance between probes b and
b{1, for example. Finally we assume conditionally conjugate







at~0 . Finally, the normal range of variability in
mRNA expression
s{2g *G(as,bs),



















































with the same assumptions on s21 , s
2
2 and k2 , k3 fixed at 1.
A summary of the model is given in the upper part of Figure 1.
Modified Probability Model for the prediction of pCR
The idea of this section raises from the question of whether or
not we could use the same latent structure underneath gene
expression and copy number variation data to make inference on a
clinical outcome of new patients in the study, in particular ut , the
pCR of patients to treatment.
The chosen approach is to state a model for ygt and wbt,
p(wbt,ygtDh) , and to assume a Bernoulli distribution for ut. This
leads us to the sought model p(utDwbt,ygt) and posterior
probabilities of ut being 1 give us a measure for the prediction
of the outcome of the new patient.
The advantages of our model with respect to, for example, a
simple logistic regression p(utDygt,wbt) are mainly the noise
probability of differential expression (B). Comparison between sample correlations and posterior probabilities of positive interaction between
platforms (C).
doi:10.1371/journal.pone.0068071.g003
Table 2. Numerosities in the training set and test set.
Training sample Test sample TOT
Positive pCR 20 11 31
No pCR 74 11 85
TOT 94 22 116
doi:10.1371/journal.pone.0068071.t002
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reduction achieved through the assumption of a latent structure
underneath our data, i.e. the latent POE scores for gene expression
and the natural variable selection allowed within the model itself;
indicators dwug and d
yu
g in equation (4) and (5) (with Bernoulli
priors with probability 1{p and p very close to 1) allow for a
reduction of the number of covariates (genes) and avoid the
problem of overestimation.
In summary, as a new patient comes into a study and we have
measurements of his gene expression and copy number variation,
we run the model p(wbt,ygtDh) and assume for his clinical outcome
ut a Bernoulli distribution with probability p . Through MCMC
methods we obtain updated posterior probabilities of ut being 1
that give us a measure for the prediction of his outcome.
In this particular case the outcome refers to the pCR to the
Figure 4. Histograms of the posterior probabilities of positive pCR in the integrated model (A) and in the marginal models,
respectively on gene expression (B) and CNA data (C).
doi:10.1371/journal.pone.0068071.g004
Figure 5. Comparison between ROC curves obtained with the
marginal and integrated model.
doi:10.1371/journal.pone.0068071.g005
Figure 6. Comparison between ROC curves obtained with the
LASSO logistic regression, respectively using single or joint
platforms.
doi:10.1371/journal.pone.0068071.g006
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treatment of patients in a breast cancer study, which is defined as a
complete disappearance of the tumor with no more than a few
scattered tumor cells detected by the pathologist in the resection
specimen [16].
As before we use a mixture model (equations 1 and 2) [15] to
introduce a trinary latent indicator variables for the CNA state for
each probe and the expression level state for each gene, and latent
Gaussian variables zwbt and z
y
gt to define a probit scores for the
trinary indicators ewbt and e
y
gt (3).
The next two equations embody our assumption that positive or
negative clinical response of patients could be related to
differential behaviour of a small subgroups of the 11,306 genes,










where ut is the clinical outcome mentioned above, measured on
the 116 patients, and dwug is a binary indicator introduced for
controlling the number of covariate in the regression.
The integration of the two platforms is implemented as a










where llg characterizes the relationship between the two platform,
dyug is a binary indicator introduced for controlling the number of
covariate in the regression and ut is the same variable as above.
As new patients tz1,:::,tzn come into the study, and
supposedly they do not have an information on pCR, an
assumption on their outcome is made, as follows:
utzi*iid Bernoulli (p) , i~1,:::,n: ð6Þ
so that we can learn about ut through the above prior and
p(wbt,ygtDut,h) , using Bayes formula and MCMC methods. The
Figure 7. Comparison between ROC curves obtained with the
integrated model and LASSO logistic regression of pCR on
copy number data.
doi:10.1371/journal.pone.0068071.g007
Table 3. List of genes which jointly show over expression and
copy number amplification in TN group.
Symbol EntrezID Cytoband postprob
E2F3 1871 6p22 0.951
MYC 4609 8q24.21 0.954
PLCG2 5336 16q24.1 0.954
PEPD 5184 19q13.11 0.954
C12orf32 83695 12p13.33 0.954
C10orf10 11067 10q11.21 0.954
FOLH1 2346 11p11.2 0.955
GTPBP2 54676 6p21 0.956
KARS 3735 16q23.1 0.957
CD14 929 5q22-q32 0.958
SHCBP1 79801 16q11.2 0.959
CHD1L 9557 1q12 0.959
CCDC86 79080 11q12.2 0.962
SLAMF7 57823 1q23.1-q24.1 0.962
CTPS 1503 1p34.1 0.962
IRAK1 3654 Xq28 0.964
C1GALT1 56913 7p14-p13 0.965
STK38 11329 6p21 0.965
AK2 204 1p34 0.966
HEPH 9843 Xq11-q12 0.966
VIM 7431 10p13 0.967
CDH3 1001 16q22.1 0.968
TRIT1 54802 1p34.2 0.969
GAS1 2619 9q21.3-q22 0.971
HLA-DRA 3122 6p21.3 0.972
ST8SIA1 6489 12p12.1-p11.2 0.973
FXYD5 53827 19q13.12 0.975
C1S 716 12p13 0.975
RECK 8434 9p13.3 0.976
C11orf75 56935 11q21 0.976
MOBKL2B 79817 9p21.2 0.977
HLA-E 3133 6p21.3 0.978
FAM107A 11170 3p21.1 0.979
ICAM1 3383 19p13.3-p13.2 0.979
INSL4 3641 9p24 0.980
PRKD3 23683 2p21 0.982
SLC2A3 6515 12p13.3 0.983
PVR 5817 19q13.2 0.984
TPX2 22974 20q11.2 0.985
NDRG1 10397 8q24.3 0.985
NFKBIE 4794 6p21.1 0.985
TIMM44 10469 19p13.3-p13.2 0.986
C1orf38 9473 1p35.3 0.986
PDSS1 23590 10p12.1 0.986
SH2D2A 9047 1q21 0.986
USP25 29761 21q11.2 0.989
HMGN4 10473 6p21.3 0.989
CHODL 140578 21q11.2 0.990
POLR1E 64425 9p13.2 0.990
Bayesian Models and Integration Genomic Platforms
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Bernoulli probability p was set to be equal to the sample
proportion of patients with positive pCR.
Priors. Priors are defined as in section 2.4, with the only
exception of the regression parameters pg and qg , and the binary
indicators dwug and d
yu
g . For both the first parameters an









with p very close to 1 to allow for the selection of a very small
subgroups of genes as covariates in the two regressions.
A summary of the model is given in the lower part of Figure 1.
Bayesian Multiplicity Control
Posterior inference for the proposed model is carried out using
MCMC simulations by a Gibbs sampling scheme, iterating from
the complete set of full conditionals reported in the appendix.
Since the analysis deals with high throughput gene expression
data and our final aim is that of selecting interesting genes [17]
multiple comparison problems arise.
A useful generalization of frequentist Type-I error rates to
multiple hypothesis testing is the false discovery rate (FDR)
introduced in Benjamini and Hochberg [18], and reviewed in a
Bayesian framework by Storey [19], [20].
Let dg denote the indicator for gene g being differentially
expressed under two biological conditions of interest (in our case
we will be facing two different indicators dg1 and dg2 whether the
comparison is ER+ vs TN or HER2+ vs TN).
H0g : dg~0; H1g : dg~1:









as the fraction of false rejections, relative to the total number of
rejections. As such it is neither Bayesian nor frequentist. Under a
Bayesian perspective, since the only unknown quantity is dg in the
numerator, it can be defined an expected FDR. Let





It was proved by M€uller et al. [21] that under several loss
functions that combine false negative and false discovery counts
the optimal rule is of the following form dg~I(rgwt) . The
problem is now that of specifying t so that the FDR is controlled at
a desirable level.
An algorithm that allows us to compute FDR levels for number
of discoveries, and therefore to select differentially expressed genes
so that the FDR level is controlled at level a , consists in sorting,
from the lowest to the highest, the marginal posterior probabilities
pg~(1{rg) , to obtain (p(1),:::,p(G)) . Thus, if p(1)=1wa, we do
not reject any null hypothesis; otherwise, if (p(1)zp(2))=2wa, we
reject H(1) only. We iterate this procedure until the first timeXG
g~1
p(g)=Gwa , and reject H(1),:::H(G{1) .
Simulation Study
We perform a small simulation study and generate data in a way
that the last 50 (out of 1,000) genes show joint differential
behaviour in copy number and RNA expression. We firstly
generated two matrices for gene expression (ygt) and copy number
log2 ratios (wbt) , respectively of dimensions G|T and B|T ,
with B~2000 probes, G~1000 genes (exactly two probes per
gene) and T~50 samples. The clinical covariate xt is set to be 1
for the first 10 patients and 0 for the remaining 40 patients.
Sample and gene effects were generated from the corresponding





m) . Observed log2 ratios and expression values were
sampled from two Gaussian distributions, respectively centred at
atzmg and 0. To induce differential joint behaviour for the last
50 genes, we did the following:
for RNA expression, we generated ygt*U({10,0) for
g[f950,:::,1000g and t[f1,:::,10g;
for copy number, we generated wbt*U({2,0) for
b[f1900,:::,2000g and t[f1,:::,10g;
The second simulation study generates data from the proposed
mixture model. We started from setting ldywg to be 2 for the first 50
genes and 0 for the remaining 950. and generated the latent scores















g [ f1,2,:::,100g and cdwg *N(0,
1
400
) for g [ f101,:::,1000g,















with proportions respectively 30% and 70%, ag*N(0,1) for
g[f1,2,:::,1000g and zygt*N(agzxtbdyg zldywg z
w
gt,1) . Once the
latent scores are generated, using (1 and 2), we generate gene
Table 3. Cont.
Symbol EntrezID Cytoband postprob
STIL 6491 1p32 0.992
BTG3 10950 21q21.1 0.992
MCM4 4173 8q11.2 0.992
doi:10.1371/journal.pone.0068071.t003
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, b [ f1,2,:::,2000g;
yz={g ~+10 and s
2
g~1, g [ f1,2,:::,1000g:
In both cases roughly 2000 iterations were needed for
convergence of the MCMC chain.
For the sake of simplicity, we report only results for the second
simulation. In Figure 2 we show the posterior probabilities of
positive interaction between platforms (fdywg =0g ), differential
CNA (fdwg =0g) and joint CNA and RNA differential expression
(fdyg=0,dwg =0g ). As we expected, posterior probabilities of
positive interaction between platforms for the first 50 genes and
posterior porbabilities of differential CNA and differential joint
behaviour for the first 100 genes are among the highest.
While these simulations merely show that our proposed models
achieve what is expected, we direct attention to selection of
differentially behaved genes with multiplicity control and then
data analysis based on breast cancer samples.
Results
We applied our model to the breast cancer data set. As
comparison, we also applied a simpler version of our models by
setting ldywg ~0 for all the genes. The simpler models assume that
the gene expression and copy numbers are independent and
therefore there is no integration. We call these simpler versions
‘‘marginal models’’.
In the upper plot of Figure 3 dots refer to the posterior
probabilities of DNA copy number amplification,
P(dwg ~1Dwb(g)t) , and over expression, P(d
y
g ~1Dygt) , based on
the marginal models; black dots highlight the list of over-expressed
genes which jointly showed copy number amplification obtained
through the integrated model. As expected the joint model selects,
coherently, mostly genes in the upper right corner, but still
differently from the intersection between the marginal ones.
A simple model checking was achieved plotting posterior
probabilities of differential gene expression and difference in
means of the gene expression measurements for TN and non TN
group. Following the same criteria, we plotted posterior probabil-
ities of positive interaction between platforms and sample
correlations. Lower plots of Figure 3 show, respectively, a very
good match between no difference in sample means and low
posterior probabilities of differential expression, and between
strong positive sample correlations and high posterior probabilities
of positive interaction between platforms.
Our main focus was on five lists of interesting genes: under (over)-
expressed genes which jointly showed DNA copy number deletion
(amplification) in TN subgroup, under (over)-expressed genes
conditional on DNA copy number aberration only in TN
subgroup and genes which showed positive interaction between
























where t~1,:::T and b(g) indicates all the probes belonging to the
gene g.
FDR levels were computed with the algorithm presented in the
previous section for the distinct rg ’s, and genes were selected
choosing a cutoff a~0:05 The lists of selected genes could be of
greater interest for clinicians since they indicate which genes show
differential expression and copy number variation in TN patients
versus patients who tests positively for ER and HER2 receptors.
On the other hand, for prediction of pCR, we split the data sets
into a training set and a test set; the training set, consisting of 94
patients, was used to obtain samples from the posterior distribution
of the parameters while the test set, consisting of 22, to check for
prediction performances through the ROC curve. Both sets were
randomly selected, and numerosities with respect to pCR of
training and test samples are reported in table 2. We constrained
numerosities in order for the test sample to be equally balanced
between positive and negative pCR, and for the training sample to
respect proportions of the original data set.
The adopted method for the estimation of the smoothed ROC
curve is LLoyd and Yong’s one [22], which is proved to perform
better than the empirical estimation. They proposed to estimate
this curve from kernel smoothing of the distribution functions of
the diagnostic measurement underlying the binary decision rule,
i.e. the conditional posterior probabilities of positive pCR, and
showed the significant accuracy achieved by this method for
realistic sample size compared with the empirical estimation.
As mentioned above, the tests we performed were done on a
sample of 22 patients, for which we had previously measured their
pCR, and are based on the posterior probabilities of the clinical
outcome being 1, P(ut~1Dwb(g)t,ygt) , obtained running the Gibbs
Sampler for 30.000 iterations. We performed the same analysis
using marginally the two platforms and obtaining respectively
posterior probabilities P(ut~1Dwb(g)t) and P(ut~1Dygt) . These
posterior probabilities, obtained through the joint and marginal
models, are showed in Figure 4.
The ROC curves are compared in Figure 5 and such
comparison confirms our choice of borrowing information
between the two genomic platforms, since the ROC curve
corresponding to the integrated model has by far the highest
Area Under the Curve, slightly below 0.9.
We finally tried and compared our method with a simple logistic
regression with LASSO variable selection (LLR) [23] [24], whose
corresponding ROC curves are plotted in Figure 6. We performed
the analysis using the package glmnet in R, and set the elastic net




and a~1 correponds to the Lasso penalty, which in this case gave
the best prediction performances.
We therefore plotted in Figure 7 the smoothed ROC curves
based on posterior probabilities of pCR obtained through the
integrated model and on predictive probabilities obtained through
LLR using only copy number variation data. The AUC under the
curve obtained through our integrated model shows to be much
higher that the one under the curve obtained through LLR.
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Discussion
We have introduced a Bayesian hierarchical model to integrate
two types of genomics data, copy number and RNA expression.
The proposed model can be easily extended to multiple platforms,
with modification to the modeling of latent probit scores. Since the
entire statistical inference is based on a coherent probability
model, scientific questions can be addressed with probability
statements, allowing for reporting uncertainty measures such as
FDR. This is the main advantage of the proposed models over
existing ones.
In table 3 we reported the list of genes which show jointly over
expression and copy number amplification in TN patients, which
was of great interest for clinicians and was also the list associated
with the lowest FDR levels. Gene MYC appeared in the list and
the result is promising since MYC is a key regulator of cell growth,
proliferation, metabolism, differentiation, and apoptosis and MYC
deregulation contributes to breast cancer development and
progression and is associated with poor outcomes. Multiple
mechanisms are involved in MYC deregulation in breast cancer,
including gene amplification, transcriptional regulation, and
mRNA and protein stabilization, which correlate with loss of
tumor suppressors and activation of oncogenic pathways [25].
Breast cancer has been classified into 5 or more subtypes based
on gene expression profiles, and each subtype has distinct
biological features and clinical outcomes. Among these subtypes,
basal-like tumor is associated with a poor prognosis and has a lack
of therapeutic targets. MYC is overexpressed in the basal-like
subtype and may serve as a target for this aggressive subtype of
breast cancer. Tumor suppressor BRCA1 inhibits MYC’s
transcriptional and transforming activity [25]. Loss of BRCA1
with MYC overexpression leads to the development of breast
cancer, especially, basal-like breast cancer. As a downstream
effector of estrogen receptor and epidermal growth factor receptor
family pathways, MYC may contribute to resistance to adjuvant
therapy. Targeting MYC-regulated pathways in combination with
inhibitors of other oncogenic pathways may provide a promising
therapeutic strategy for breast cancer, the basal-like subtype in
particular [26].
As far as the model is concerned, there are a few possible
weaknesses in the procedure, mainly related to the prior
specification for parameters d
0
gs , related to differential expression
and prediction. We were dealing with highly parametrized models
and few observations data sets, reason why we chose some easier
shortcuts in order to achieve faster MCMC convergency. Some
interesting modifications of our prior specifications are now to be
implemented, since we found in literature new and more efficient
approaches to the issue of sparsity, such as the horseshoe prior
[27].
Also, it was very hard to compare our models’ performances
with other methods, either due to the lack of codes or to the
scarcity of works on the specific topic of prediction using
integrated genomic platforms; we therefore chose a simple LASSO
logistic regression which showed to be a poor fit for this particular
data and this is mainly due to the high correlation between them.
Future work includes the development of models for integration
of three or more platforms, and the extension to new type of
genomics data, such as next-generation sequencing (NGS) data. In
the latter case, the main challenge is the inclusion of a model for
the count data from the NGS experiment. The intuitive statistical
method for such an extension would be a graphical model, where
network priors will be considered treating each platform as a node,
and edges among the nodes will be interpreted as dependence
between platforms.
Finally, all this project was focused on a specific data set, with
rather particular features. The natural hierarchical structure and
correlation between DNA and RNA makes very hard to think of
the application of our methodology to different problems, though
an interesting path to follow could be that of demographical
sciences, where this hierarchical structure could be found for
example in data at country level and regional level.
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